Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FTC refunds diet pill customers

This article was originally published in The Tan Sheet

Executive Summary

The Federal Trade Commission will accept refund requests until Oct. 27 from customers who bought CortiSlim and CortiStress products. CortiSlim advertising made false and unsubstantiated weight loss claims and CortiStress advertising used false and unsubstantiated disease prevention claims, according to FTC (1"The Tan Sheet" Jan. 8, 2007. p. 4). The settlement between FTC and CortiSlim and CortiStress marketers - idenfited by the commission as Stephen F. Cheng and Window Rock Enterprises Inc., and Gregory S. Cynaumon and Infinity Advertising Inc. - included money for consumer refunds with the actual refund depending on the number of customers who apply. The refund is available to those who purchased the products between Aug. 1, 2003, and May 31, 2006...

You may also be interested in...

FTC Supplement Settlements Spotlight Bayer, Mark First Hoodia Action

Bayer "went too far" with weight-loss and -control claims for its One-A-Day WeightSmart product and violated a 1991 sanction the product's previous owner agreed to, the Federal Trade Commission said Jan. 4 when it announced a record $3.2 million fine against the consumer healthcare giant

EU Notified Body Association Takes Steps To Allay EC’s Virtual Audit Fears

The European Commission has reluctantly allowed virtual audits in the context of new MDR and IVDR. The EU notified body association is helping the collective effort to meet its strict requirements.

New UK Biosimilars Pathway Suffers Setback

The UK’s implementation of a new national licensing framework for biosimilars has been pushed back from the start of 2021, with the MHRA citing “intense COVID-19 activities” as the cause of an indefinite delay in the consultation process.





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts